National Center for Advancing and Translational Sciences Genetic and Rare Diseases Information Center, a program of the National Center for Advancing and Translational Sciences

Cutaneous mastocytosis



Cutaneous mastocytosis is a form of mastocytosis that primarily affects the skin. There are three main forms of the condition: maculopapular cutaneous mastocytosis (also called urticaria pigmentosa), solitary cutaneous mastocytoma, and diffuse cutaneous mastocytosis. There is also an exteremely rare form called telangiectasia macularis eruptiva perstans. The signs, symptoms and severity of the condition vary by subtype.[1][2][3] Cutaneous mastocytosis is usually caused by changes (mutations) in the KIT gene. Most cases are caused by somatic mutations which are not inherited or passed on to the next generation.[1] However, it can rarely affect more than one family member and be inherited in an autosomal dominant manner.[4] Treatment is usually symptomatic and may include oral antihistamines, topical steroids, and/or photochemotherapy.[1][5]

Last updated: 2/23/2015

Cutaneous mastocytosis is a form of mastocytosis that primarily affects the skin. There are three main forms that vary in severity: maculopapular cutaneous mastocytosis (also called urticaria pigmentosa), solitary cutaneous mastocytoma, and diffuse cutaneous mastocytosis. There is also an exteremely rare form called telangiectasia macularis eruptiva perstans.[2][6]

Maculopapular cutaneous mastocytosis, the most common form of cutaneous mastocytosis, is characterized by itchy, brown patches on the skin. Although these patches may be mistaken for freckles or bug bites initially, they typically persist and gradually increase in number over several months to years. In young children, the patches may form a blister if itched or rubbed. Itching may worsen with changes in temperature, strenuous activity, emotional stress, and/or certain medications. Maculopapular cutaneous mastocytosis is most commonly seen in infants and young children and often fades by the teenaged years. In some cases, this condition may not develop until adulthood. These later onset cases generally last long-term and are more likely to progress to systemic mastocytosis.[2][6][7]

Solitary cutaneous mastocytoma is a localized form of cutaneous mastocytosis. Like maculopapular cutaneous mastocytosis, this form is typically diagnosed in young children. However, it is characterized by an itchy area of reddish or brown skin that is often thickened. When itched, these patches of skin may swell, redden, and/or blister. This form typically resolves spontaneously with age.[2][6][8]

Diffuse cutaneous mastocytosis, the most severe form of cutaneous mastocytosis, usually develops in infancy. Unlike the other forms of cutaneous mastocytosis, it affects most or all of the skin rather than appearing as distinct patches. In people affected by this condition, the skin is leathery and thickened. It may appear normal, yellowish-brown, or red in color. In some cases, there may also be widespread blistering. Additional symptoms may include hypotension, diarrhea, gastrointestinal bleeding, reddening of the skin (flushing), and anaphylactic shock.[1][2][6]

The rarest form of cutaneous mastocytosis is called telangiectasia macularis eruptiva perstans. Unlike the other forms of cutaneous mastocytosis, this form is primarily diagnosed in adults and is generally not associated with pruritus and blistering. People affected by this condition have persistent brown patches of skin and extensive telegiactasia. Rarely, this form may progress to systemic mastocytosis.[1][2]



Last updated: 2/22/2015

This table lists symptoms that people with this disease may have. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. This information comes from a database called the Human Phenotype Ontology (HPO) . The HPO collects information on symptoms that have been described in medical resources. The HPO is updated regularly. Use the HPO ID to access more in-depth information about a symptom.

Showing of 31 |
Medical Terms Other Names
Learn More:
HPO ID
80%-99% of people have these symptoms
Abnormality of skin pigmentation
Abnormal pigmentation
Abnormal skin color
Abnormal skin pigmentation
Abnormality of pigmentation
Pigmentary changes
Pigmentary skin changes
Pigmentation anomaly
[ more ]
0001000
Cutaneous mastocytosis 0200151
Macule
Flat, discolored area of skin
0012733
Multiple cafe-au-lait spots 0007565
Papule 0200034
Pruritus
Itching
Itchy skin
Skin itching
[ more ]
0000989
30%-79% of people have these symptoms
Abdominal pain
Pain in stomach
Stomach pain
[ more ]
0002027
5%-29% of people have these symptoms
Abnormal blistering of the skin
Blistering, generalized
Blisters
[ more ]
0008066
Alopecia
Hair loss
0001596
Anxiety
Excessive, persistent worry and fear
0000739
Asthma 0002099
Cardiac arrest
Heart stops beating
0001695
Cough
Coughing
0012735
Depressivity
Depression
0000716
Diarrhea
Watery stool
0002014
Dyspnea
Trouble breathing
0002094
Erythroderma 0001019
Fatigue
Tired
Tiredness
[ more ]
0012378
Gastrointestinal hemorrhage
Gastrointestinal bleeding
0002239
Headache
Headaches
0002315
Hepatomegaly
Enlarged liver
0002240
Hypercalcemia
High blood calcium levels
Increased calcium in blood
[ more ]
0003072
Hypotension
Low blood pressure
0002615
Increased bone mineral density
Increased bone density
0011001
Myeloproliferative disorder 0005547
Nausea and vomiting 0002017
Osteoporosis 0000939
Recurrent fractures
Increased fracture rate
Increased fractures
Multiple fractures
Multiple spontaneous fractures
Varying degree of multiple fractures
[ more ]
0002757
Sarcoma
Cancer of connective tissue
Malignant connective tissue tumor
[ more ]
0100242
Splenomegaly
Increased spleen size
0001744
Telangiectasia of the skin 0100585
Showing of 31 |
Last updated: 7/1/2020

Most cases of cutaneous mastocytosis are caused by changes (mutations) in the KIT gene. This gene encodes a protein that helps control many important cellular processes such as cell growth and division; survival; and movement. This protein is also important for the development of certain types of cells, including mast cells (immune cells that are important for the inflammatory response). Certain mutations in the KIT gene can leads to an overproduction of mast cells. In cutaneous mastocytosis, excess mast cells accumulate in the skin, leading to the many signs and symptoms of the condition.[1][9]
Last updated: 2/23/2015

Most cases of cutaneous mastocytosis are not inherited. They occur spontaneously in families with no history of the condition and are due to somatic changes (mutations) in the KIT gene. Somatic mutations occur after conception and are only present in certain cells. Because they are not present in the germ cells (egg and sperm), they are not passed on to the next generation.[1][6]

Cutaneous mastocytosis can rarely affect more than one family member. In these cases, the condition is typically inherited in an autosomal dominant manner.[4][10] This means that to be affected, a person only needs a change (mutation) in one copy of the responsible gene in each cell. A person with familial cutaneous mastocytosis has a 50% chance with each pregnancy of passing along the altered gene to his or her child.
Last updated: 2/23/2015

A diagnosis of cutaneous mastocytosis is typically suspected based on the presence of suspicious signs and symptoms. A skin biopsy that reveals a high number of mast cells (immune cells that are important for the inflammatory response) confirms the diagnosis.[1][6]

Unfortunately it can sometimes be difficult to differentiate cutaneous mastocytosis from systemic mastocytosis. Additional tests may, therefore, be ordered to further investigate the risk for systemic disease. A bone marrow biopsy and specialized blood tests may be recommended in adults with cutaneous mastocytosis since they are at a higher risk for systemic mastocytosis. Affected children typically do not undergo a bone marrow biopsy unless blood tests are abnormal.[11]
Last updated: 2/23/2015

Testing Resources

  • The Genetic Testing Registry (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.
  • Orphanet lists international laboratories offering diagnostic testing for this condition.

Although there is currently no cure for cutaneous mastocytosis, treatments are available to manage the symptoms of the condition. In general, it is recommended that affected people avoid things that trigger or worsen their symptoms when possible. Certain medications such as oral antihistamines and topical steroids are often prescribed to relieve symptoms. Affected adults may also undergo photochemotherapy which can help alleviate itching and improve the appearance of the patches; however, the condition is likely to recur within six to twelve months of the last treatment. People at risk for anaphylactic shock and/or their caregivers should be trained in how to recognize and treat this life-threatening reaction and should carry an epinephrine autoinjector at all times.[1][5][6]
Last updated: 2/23/2015

The long-term outlook (prognosis) for people affected by cutaneous mastocytosis varies depending on the age at diagnosis. The prognosis is typically excellent in children who develop symptoms before age 2 as approximately 80% of these cases resolve before puberty. The remaining cases may persist as cutaneous mastocytosis or progress to systemic disease. Risk factors for progression to systemic mastocytosis include later onset of the skin symptoms (after age 2), persistence of skin symptoms past adolescence, and abnormal blood counts. In very rare cases, the condition may progress to aggressive forms of mast cell disease such as mast cell sarcoma (solid tumor of cancerous mast cells) or mast cell leukemia (rare disease of circulating cancerous mast cells).[3] [5]

Cutaneous mastocytosis that develops after age 2 or in adults generally does not resolve. Approximately 90% of affected adults also have evidence of systemic mastocytosis at the time of diagnosis. Later onset cases also have a higher risk of malignant (cancerous) forms of mast cell disease.[3] [5]
Last updated: 2/24/2015

If you need medical advice, you can look for doctors or other healthcare professionals who have experience with this disease. You may find these specialists through advocacy organizations, clinical trials, or articles published in medical journals. You may also want to contact a university or tertiary medical center in your area, because these centers tend to see more complex cases and have the latest technology and treatments.

If you can’t find a specialist in your local area, try contacting national or international specialists. They may be able to refer you to someone they know through conferences or research efforts. Some specialists may be willing to consult with you or your local doctors over the phone or by email if you can't travel to them for care.

You can find more tips in our guide, How to Find a Disease Specialist. We also encourage you to explore the rest of this page to find resources that can help you find specialists.

Healthcare Resources

  • The Mastocytosis Society has a listing of Medical Research Centers that specialize in mastocytosis. Click on the link to view this list which includes centers in the United States and Europe.
  • The Mastocytosis Society maintains a Physician Database where you can search for physicians that specialize in Cutaneous mastocytosis.

Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.

Clinical Research Resources

  • ClinicalTrials.gov lists trials that are related to Cutaneous mastocytosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

    Please note: Studies listed on the ClinicalTrials.gov website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.
  • Orphanet lists European clinical trials, research studies, and patient registries enrolling people with this condition. 

Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.

Organizations Supporting this Disease

Social Networking Websites

  • RareConnect has an online community for patients and families with this condition so they can connect with others and share their experiences living with a rare disease. The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).

These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.

Where to Start

  • DermNet NZ is an online resource about skin diseases developed by the New Zealand Dermatological Society Incorporated. DermNet NZ provides information on maculopapular cutaneous mastocytosis and mastocytoma, which are two specific types of cutaneous mastocytosis.
  • MedlinePlus was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.
  • The Merck Manuals Online Medical Library provides information on this condition for patients and caregivers. 
  • The National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
  • The Mastocytosis Society provides information about mast cell diseases, including Cutaneous mastocytosis.

In-Depth Information

  • Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
  • The Merck Manual for health care professionals provides information on Cutaneous mastocytosis.
  • The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
  • Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.
  • PubMed is a searchable database of medical literature and lists journal articles that discuss Cutaneous mastocytosis. Click on the link to view a sample search on this topic.

Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know.


  1. Mastocytosis. DermNet NZ. September 2014; http://dermnetnz.org/systemic/mastocytosis.html.
  2. Castells MC and Akin C. Mastocytosis (cutaneous and systemic): Epidemiology, pathogenesis, and clinical manifestations. UpToDate. December 5, 2016; http://www.uptodate.com/contents/mastocytosis-cutaneous-and-systemic-epidemiology-pathogenesis-and-clinical-manifestations.
  3. Habashy J and Robles DT. Mastocytosis. Medscape Reference. May 15, 2017; http://emedicine.medscape.com/article/1057932-overview.
  4. Fett NM, Teng J, and Longley BJ. Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations. Am J Dermatopathol. February 2013; 35(1):113-116. https://www.ncbi.nlm.nih.gov/pubmed/22892471.
  5. CastellsMC and Akin C. Treatment and prognosis of cutaneous mastocytosis. UpToDate. June 5 2015; http://www.uptodate.com/contents/treatment-and-prognosis-of-cutaneous-mastocytosis.
  6. Bundra K and Akin C. Mastocytosis. National Organization for Rare Disorders. 2017; https://rarediseases.org/rare-diseases/mastocytosis/.
  7. Maculopapular cutaneous mastocytosis. DermNet NZ. November 2014; http://dermnetnz.org/colour/urticaria-pigmentosa.html.
  8. Mastocytoma. DermNet NZ. March 2014; http://dermnetnz.org/lesions/mastocytoma.html.
  9. KIT. Genetics Home Reference. September 2014; http://ghr.nlm.nih.gov/gene/KIT.
  10. Mast Cell Disease. Online Mendelian Inheritance in Man (OMIM). January 24, 2012; http://omim.org/entry/154800.
  11. Mariana C Castells, MD, PhD; Cem Akin, MD, PhD. Evaluation and diagnosis of mastocytosis (cutaneous and systemic). UpToDate. July 25 2015; https://www.uptodate.com/contents/mastocytosis-cutaneous-and-systemic-evaluation-and-diagnosis-in-adults.